| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
|
Arthritis Rheum
|
2011
|
3.81
|
|
2
|
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.
|
Arthritis Rheum
|
2009
|
3.34
|
|
3
|
Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.
|
Arthritis Rheum
|
2008
|
2.63
|
|
4
|
Novel evidence-based systemic lupus erythematosus responder index.
|
Arthritis Rheum
|
2009
|
2.58
|
|
5
|
TGF-beta requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25+ regulatory cells.
|
J Immunol
|
2006
|
2.25
|
|
6
|
Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice.
|
Arthritis Rheum
|
2012
|
2.21
|
|
7
|
Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis.
|
Arthritis Rheum
|
2003
|
2.21
|
|
8
|
Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.
|
Arthritis Rheum
|
2006
|
2.17
|
|
9
|
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.
|
Arthritis Res Ther
|
2008
|
2.15
|
|
10
|
BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases.
|
J Immunol
|
2002
|
1.77
|
|
11
|
Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
|
J Rheumatol
|
2013
|
1.72
|
|
12
|
Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease.
|
J Immunol
|
2009
|
1.55
|
|
13
|
Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study.
|
Arthritis Res Ther
|
2009
|
1.54
|
|
14
|
Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF.
|
J Immunol
|
2006
|
1.43
|
|
15
|
Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway.
|
J Immunol
|
2009
|
1.40
|
|
16
|
B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels.
|
Arthritis Res Ther
|
2006
|
1.36
|
|
17
|
Cytokine disturbances in systemic lupus erythematosus.
|
Arthritis Res Ther
|
2011
|
1.21
|
|
18
|
Antibody-mediated coengagement of FcγRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus.
|
J Immunol
|
2011
|
1.16
|
|
19
|
Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE.
|
Ann Rheum Dis
|
2011
|
1.12
|
|
20
|
B Cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice.
|
J Immunol
|
2011
|
1.08
|
|
21
|
Local BLyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation.
|
J Exp Med
|
2013
|
1.06
|
|
22
|
Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future.
|
Autoimmunity
|
2010
|
0.98
|
|
23
|
BAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitis.
|
PLoS One
|
2011
|
0.97
|
|
24
|
Racial/ethnic differences in the use of biologic disease-modifying antirheumatic drugs among California Medicaid rheumatoid arthritis patients.
|
Arthritis Care Res (Hoboken)
|
2013
|
0.96
|
|
25
|
Increased CXCL8 (IL-8) expression in Multiple Sclerosis.
|
J Neuroimmunol
|
2004
|
0.96
|
|
26
|
Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort.
|
Arthritis Rheum
|
2010
|
0.94
|
|
27
|
Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor.
|
Arthritis Rheum
|
2013
|
0.87
|
|
28
|
BAFF- and APRIL-dependent maintenance of antibody titers after immunization with T-dependent antigen and CD1d-binding ligand.
|
J Immunol
|
2013
|
0.84
|
|
29
|
Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fcγ receptor IIb inhibitory receptor.
|
Arthritis Rheumatol
|
2014
|
0.82
|
|
30
|
Tear cathepsin S as a candidate biomarker for Sjögren's syndrome.
|
Arthritis Rheumatol
|
2014
|
0.82
|
|
31
|
Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial.
|
J Rheumatol
|
2012
|
0.82
|
|
32
|
Patients with inflammatory arthritic diseases harbor elevated serum and synovial fluid levels of free and immune-complexed glucose-6-phosphate isomerase (G6PI).
|
Biochem Biophys Res Commun
|
2006
|
0.82
|
|
33
|
B lymphocyte stimulator expression in pediatric systemic lupus erythematosus and juvenile idiopathic arthritis patients.
|
Arthritis Rheum
|
2009
|
0.81
|
|
34
|
In vitro and in vivo T cell oligoclonality following chronic stimulation with staphylococcal superantigens.
|
Clin Immunol
|
2003
|
0.80
|
|
35
|
Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes).
|
Arthritis Res Ther
|
2010
|
0.80
|
|
36
|
Incremental expenditure of biologic disease modifying antirheumatic treatment using instrumental variables in panel data.
|
Health Econ
|
2012
|
0.76
|
|
37
|
A TLR9-dependent checkpoint governs B cell responses to DNA-containing antigens.
|
J Clin Invest
|
2017
|
0.75
|
|
38
|
New and promising treatments for rheumatoid arthritis.
|
Am J Orthop (Belle Mead NJ)
|
2007
|
0.75
|